About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

RECRUITINGPhase 2

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive Tumors

NCT04879121•M.D. Anderson Cancer Center

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

Interventions

Larotrectinib Sulfate

Locations

1

United States

Locations (1)

M D Anderson Cancer Center

Houston, Texas, United States

Key Dates

Start Date

April 30, 2021

Primary Completion Date

November 11, 2027

Completion Date

November 11, 2027

Last Updated

April 16, 2026

Related Studies

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

NCT04693377

Castration-Resistant Prostate CarcinomaMetastatic Colorectal Carcinoma+16 more

RECRUITINGPhase 2

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

NCT03907475

Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

RECRUITINGPhase 3

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NCT06500455

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+8 more

RECRUITINGPhase 2

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

NCT06311214

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

RECRUITINGPhase 1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+6 more

RECRUITINGPhase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View all related studies

Sponsors

Lead Sponsor

M.D. Anderson Cancer Center

Collaborators

National Cancer Institute (NCI)

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 16, 2026Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions